Flow Neuroscience

Flow Neuroscience operates at the intersection of medical devices, digital therapeutics, and consumer-oriented mental healthcare. Its core proposition combines a wearable transcranial direct current stimulation headset with an app that supports behavioral exercises, symptom tracking, treatment guidance, exercise, and sleep routines. The company’s clearest differentiation is the attempt to move a clinician-supervised neuromodulation approach into the home through a prescription pathway. FDA clearance for at-home use and the 2026 US launch of FL-100 give Flow a regulatory and commercialization milestone that many wellness-oriented brain-stimulation products do not have. The company also addresses both physiological and behavioral elements of major depressive disorder rather than offering stimulation hardware alone. Flow remains a private company with approximately 11–50 employees and disclosed funding of $12.56 million, suggesting a focused scale relative to larger medical-device and pharmaceutical incumbents. Its market position therefore depends on demonstrating clinical outcomes, patient adherence, reimbursement access, and safe expansion beyond early adopters.

Flow Neuroscience’s trajectory shows a progression from early hardware development toward regulated, at-home treatment delivery. The company was founded in 2016, raised a $1.1 million Seed round in January 2018, followed by a $1.49 million Seed round in July 2019, and completed a $9.96 million Series A in August 2021 led by Khosla Ventures, Redstone.VC, SwissHealth Ventures, and Zühlke Ventures AG. It added a convertible note in December 2020, non-equity assistance from MedTech Innovator in June 2023, and another convertible note reported at $13 million in July 2024. The 2021 acquisition of Halo Neuroscience provided an additional strategic step in neurostimulation. The most significant inflection point came in late 2025 and early 2026, when Flow obtained FDA clearance for at-home use in major depressive disorder and then launched FL-100 in the US on Sep 1, 2026. The company’s app downloads remain modest in the available measurement snapshot, with 804 total downloads reported across listed applications, while its employee band remains 11–50. Future growth will depend on converting regulatory access into prescription volume, clinician adoption, recurring treatment engagement, and broader geographic distribution.